Skip to content

GHRP-6

A synthetic growth hormone secretagogue known for potent GH release and significant appetite stimulation through ghrelin receptor activation.

CModerateModerate Data
Last updated 32 citations
TL;DR

GHRP-6 is the original growth hormone-releasing peptide — the 1984 prototype the whole GHRP family descends from — and its defining feature is hunger. It activates the ghrelin receptor hard enough to make appetite the point rather than the side effect, which is why it is still chosen for wasting and cachexia and why it is a poor choice for fat loss. Its GH effect is real but requires your own GHRH to work, and it raises cortisol and prolactin more than GHRP-2 or ipamorelin do. Two things are commonly overstated: it does not deepen slow-wave sleep (it increases stage 2 sleep), and its one Phase III trial — EGF plus GHRP-6 in acute ischemic stroke — missed its primary endpoint. Not approved anywhere, and named on the WADA Prohibited List under S2.2.4.

What is GHRP-6?

GHRP-6 is one of the earliest synthetic growth hormone releasing peptides developed. It acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is notable for its strong appetite-stimulating effects, which can be beneficial for those needing to increase caloric intake but may be undesirable for others.

What GHRP-6 Is Investigated For

GHRP-6 is investigated for growth hormone release, appetite stimulation, gastric motility, and body composition, with its most distinctive pharmacological feature being pronounced ghrelin-receptor-mediated hunger induction. The strongest evidence is for the appetite effect itself — well-characterized acute hunger within 15–60 minutes of injection, making GHRP-6 the preferred GHRP specifically for cachexia, wasting, and medication-induced appetite suppression contexts where stimulating caloric intake is the therapeutic goal. Its GH-releasing effect is moderate and less potent than GHRP-2 or hexarelin, and it elevates cortisol and prolactin more than either, making it a poor first-line choice for body-composition goals. The honest caveats are that GHRP-6 is not FDA-approved for any indication, long-term human safety data outside diagnostic testing is essentially absent, and it is named on WADA's Prohibited List (S2.2.4) at all times with routine LC-MS/MS urinary detection. As the foundational first-generation GHRP from the Bowers-Momany program at Tulane, GHRP-6's historical importance is enormous, but modern compound selection generally favors GHRP-2 or ipamorelin for GH goals — reserving GHRP-6 for the specific appetite-stimulation use case.

Growth hormone release
Moderate70%
Appetite stimulation
Moderate70%
Neuroprotection in acute ischemic stroke (with EGF) — tested and negative on its primary endpoint
Preliminary30%
Gastric motility improvement
Emerging50%
Body composition changes
Emerging50%

History & Discovery

GHRP-6 is the foundational first-generation synthetic growth hormone-releasing peptide, emerging from the sustained medicinal-chemistry collaboration between Frank Momany and Cyril Bowers at Tulane University during the 1980s. Their work began from the observation that a met-enkephalin analog could release GH in pituitary cell cultures, and they iterated through a series of short synthetic peptides that retained GH-releasing potency while stripping away opioid activity. The hexapeptide sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 emerged as the first consistently active compound, first described in the peer-reviewed literature in the early 1980s and formalized as GHRP-6 in subsequent work. Its discovery predated the identification of the underlying receptor: the GHS-R1a receptor was not cloned until 1996, and its endogenous ligand ghrelin was not identified until 1999, meaning GHRP-6 spent more than a decade as a pharmacologically orphan compound whose mechanism was evident only in retrospect. GHRP-6 was explored in early human trials for GH-deficient children and as a diagnostic tool, but it was never approved as a therapeutic drug in any major market. Its historical importance is as the reference first-generation GHRP — the compound against which all subsequent GHRPs (GHRP-2, hexarelin, ipamorelin) were benchmarked. The two features that most shaped its later clinical identity were pronounced appetite stimulation (a ghrelin-receptor-mediated effect that tracks the discovery of ghrelin as the endogenous hunger hormone) and meaningful cortisol and prolactin elevation at clinical doses. GHRP-6 migrated into the research-chemical and compounding-pharmacy market during the 2000s, and today is most commonly chosen specifically for the appetite-stimulation use case — cachexia, wasting, medication-induced appetite suppression — where the feature is the point rather than an unwanted side effect.

How It Works

GHRP-6 mimics the hunger hormone ghrelin, telling your brain to release growth hormone and increase appetite. It creates a strong growth hormone pulse but also significantly increases the desire to eat.

GHRP-6 is a potent agonist of the GHS-R1a receptor with additional effects on cortisol and prolactin release through ACTH stimulation. It triggers GH release through IP3/DAG-mediated calcium signaling in pituitary somatotrophs. Its strong ghrelin-mimetic activity in the hypothalamus drives appetite stimulation through NPY/AgRP neuron activation.

Evidence Snapshot

Overall Confidence65%

Human Clinical Evidence

Moderate for endocrine pharmacology, weak for outcomes. GH release kinetics are well characterized: GHRP-6 requires endogenous GHRH for a full response (the GH rise fell from 33.8 to 6.2 mcg/l when GHRH was blocked, PMID 9543138), its GH effect is preserved in older adults where the GHRH response declines (PMID 7734029), and human pharmacokinetics are established (distribution half-life 7.6 minutes, elimination 2.5 hours, PMID 23099431). It reliably activates the HPA axis, raising ACTH roughly three-fold in Cushing's disease (PMID 12809173), and has been evaluated as a diagnostic alternative to the insulin tolerance test with only moderate accuracy (71% sensitivity, 78% specificity, PMID 19946832). The one Phase III trial in any indication — EGF plus GHRP-6 in acute ischemic stroke — missed its primary endpoint (PMID 42462342). There is no controlled human trial of GHRP-6 for body composition, and the appetite effect, though consistently described, has not been quantified in a placebo-controlled GHRP-6 trial the way it has for GHRP-2.

Animal / Preclinical

Extensive, and currently the most active area of GHRP-6 research. Beyond pituitary pharmacology, rodent work reports preserved left ventricular systolic function in doxorubicin cardiotoxicity (PMID 38873418), attenuated post-infarct ventricular remodeling (PMID 41901314), reduced lipopolysaccharide-induced acute lung injury and subsequent fibrosis (PMID 41534456), accelerated renal tissue repair (PMID 25194405), and a hydrogel formulation for acute kidney injury acting through the mTOR-P70 pathway (PMID 41327290). The consistent theme is cytoprotection in ischemic and toxic tissue injury, mediated by mechanisms largely separate from GH release. None of it has yet produced a positive human outcome trial.

Mechanistic Rationale

Strong. GHS-R1a pharmacology is well-characterized.

Research Gaps & Open Questions

What the current literature has not yet settled about GHRP-6:

  • 01Long-term (>12 month) human safety data outside diagnostic-test populations is essentially absent.
  • 02Whether GHRP-6's cortisol and prolactin elevation at chronic wellness-range doses produces clinically meaningful HPA-axis or reproductive-endocrine consequences over months has not been characterized.
  • 03The magnitude and durability of the appetite-stimulation effect in human wasting and cachexia populations has not been quantified in modern placebo-controlled trials, even though this is the use case most frequently cited for GHRP-6 specifically.
  • 04Head-to-head comparisons between GHRP-6 and GHRP-2 or ipamorelin on long-duration body-composition and functional endpoints in non-deficient adults are absent.
  • 05Whether GHRP-6's renal, cardiac and pulmonary preclinical signals translate to human clinical outcomes remains unproven — and the one Phase III attempt did not demonstrate it. The Cuban CIGB programme took the EGF plus GHRP-6 combination into COURAGE-2, a 188-patient open-label randomized trial in acute ischemic stroke, and the trial MISSED its primary endpoint: in the intention-to-treat population there were no differences in modified Rankin Scale, Barthel index or survival (Hernández-Bernal et al., J Clin Neurosci 2026, PMID 42462342). A post-hoc subgroup of 27 severe-stroke patients (NIHSS >= 15) showed less disability and lower mortality, which the authors offer as grounds for a further trial in that subpopulation rather than as a result. Serious adverse events were numerically more common on treatment (30/95 vs 18/93, OR 1.92). Whether the subgroup signal is real is now the open question.
  • 06The preclinical biology behind the stroke programme is better characterized than its clinical effect. Rodríguez-Ulloa and colleagues (Pharmacol Rep 2026, PMID 42258095) used discovery proteomics in a rat middle-cerebral-artery-occlusion MODEL — not in patients — identifying 40 differentially modulated proteins at 3 hours and 223 at 24 hours after treatment, with consistent changes in neurotransmitter-transport, anti-apoptotic and mitochondrial proteins in the ischemic penumbra. Risco-Acevedo et al. (Neurotox Res 2026, PMID 42399524) reported that EGF plus GHRP-6 attenuated cognitive decline in aged and streptozotocin-treated C57BL/6 mice, upregulating Hmox1, Creb1 and Olig1 while reducing Nfkb1. Whether any of this explains a human benefit that the Phase III did not detect is unresolved.
  • 07The doses used in the stroke programme bear no relationship to the doses discussed for wellness use. COURAGE-2 gave 5 mg of GHRP-6 intravenously twice daily — 10 mg a day, roughly 50 to 100 times the 100 to 200 mcg subcutaneous doses described in the dosing section of this page. No one has studied whether the microgram-range subcutaneous protocols produce any of the tissue-protective effects seen at milligram intravenous doses, and it should not be assumed that they do.
  • 08Optimal dosing design for the appetite-specific use case — dose, timing relative to meals, stacking vs. monotherapy — has not been standardized in published clinical literature.

Forms & Administration

GHRP-6 is administered via subcutaneous injection, typically 2-3 times daily on an empty stomach. It is often combined with a GHRH analog. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

Protocols commonly discussed for GHRP-6 run 100–200 mcg per dose, most frequently 100 mcg per injection two to three times daily. The dose-response curve flattens above roughly 200 mcg per dose; higher single doses do not produce proportionally greater GH release and do disproportionately elevate cortisol, prolactin, and ACTH. When GHRP-6 is chosen specifically for appetite stimulation in wasting or cachexia contexts, the pre-meal 100 mcg dose is the most common configuration because the appetite effect is acute and ghrelin-receptor-mediated.

Frequency

GHRP-6 clears quickly from plasma in two phases — a distribution half-life of about 7.6 minutes and an elimination half-life of roughly 2.5 hours after an intravenous bolus (Cabrales et al., PMID 23099431) — and its GH-releasing action is pulsatile rather than sustained, so dosing is typically split across two to three discrete pulses per day — commonly morning, pre-meal or midday, and bedtime. When the appetite effect is the therapeutic goal, timing 15–30 minutes before a target meal aligns the ghrelin-receptor activation with the intended feeding window. When GH release is the primary goal, timing on an empty stomach matters more than meal-alignment. The standard dual-pathway stacking rationale with a GHRH analog applies to GHRP-6 as it does to the other GHRPs: GHRP-6 acts at the ghrelin/GHS-R1a receptor, the GHRH analog at the GHRH receptor, and the two together produce a larger synergistic GH pulse than either alone.

Timing Considerations

Time of day

Bedtime is the most common window, aligned with the natural nocturnal GH pulse; multi-dose protocols typically add a mid-morning fasted dose and a pre-workout dose.

Relative to meals

Fasted — at least 30 minutes before food and 2+ hours after a meal. Elevated insulin and circulating amino acids substantially blunt GH release, so meal timing directly affects pulse amplitude.

Relative to exercise

Independent of training, though some users add a pre-workout dose on training days for an additional GH pulse around exercise. Expect meaningful appetite stimulation in the 30–60 min window after injection, which may or may not be desirable depending on your goal.

Cycle Length

Commonly discussed protocols run 8–12 weeks on followed by a 4-week break. Pituitary desensitization with chronic ghrelin-receptor stimulation is a theoretical concern, though GHRP-6 appears less prone to tachyphylaxis than hexarelin. No long-duration human trial has directly compared continuous versus cycled GHRP-6 dosing. In cachexia and wasting use cases, continuous use during active illness is more commonly discussed than in wellness use.

Protocol Notes

GHRP-6 is supplied as a lyophilized powder, typically 5 mg or 10 mg per vial, reconstituted in bacteriostatic water. A 5 mg vial in 2 mL of BAC water yields 2,500 mcg/mL, making 100 mcg roughly 0.04 mL or 4 units on an insulin syringe. Subcutaneous injection into the abdominal fat pad is the standard route. Because GHRP-6 acts through the ghrelin receptor, the interaction with eating is central to dosing design. For GH-release goals, injection at least 30 minutes before eating or 2+ hours after a meal is standard, because circulating amino acids and elevated insulin blunt GH release. For appetite-stimulation goals, injection 15–30 minutes before a target meal leverages the acute hunger effect. Bedtime dosing is often avoided in users for whom the appetite stimulation is unwanted, since it can drive nighttime eating. When stacked with CJC-1295 no-DAC or sermorelin, both peptides are typically drawn into the same syringe and injected together.

GHRP-6 is not FDA-approved for any indication. The numbers above describe commonly-referenced protocols, not a prescription. Use should be supervised by a qualified clinician with appropriate IGF-1, glucose, cortisol, and prolactin monitoring given GHRP-6's off-target hormonal effects.

Timeline of Effects

Onset

Appetite stimulation is the first and most distinctive GHRP-6 signal — pronounced hunger typically appears within 15–60 minutes of injection, tracking the acute ghrelin-receptor activation. Sleep changes are real but narrower than usually claimed: in the one controlled overnight study, GHRP-6 increased stage 2 sleep while leaving slow-wave sleep unchanged (PMID 7617137), so this is altered sleep architecture rather than deeper sleep. Subjective recovery improvement follows the general GHRP pattern, typically within 1–2 weeks of consistent daily dosing. The acute GH pulse is immediate (peak within 15–30 minutes of injection), but downstream IGF-1 elevation requires several days of repeat dosing to accumulate meaningfully in serum.

Peak Effect

Serum IGF-1 typically rises progressively over the first 3–6 weeks of consistent dosing and plateaus. The magnitude of IGF-1 elevation achievable with GHRP-6 at typical wellness doses is modestly lower than with GHRP-2 or hexarelin at comparable dosing; its strongest acute effect remains appetite rather than GH release per se. Body-composition changes in wasting and cachexia populations — where the appetite effect drives meaningful caloric intake gains — can become visible within weeks, because the primary mechanism is behavioral (increased eating) as much as it is endocrine.

After Discontinuation

Because GHRP-6 does not suppress endogenous GHRH or ghrelin production, endogenous pulsatile GH secretion returns to baseline within days of stopping dosing. Appetite normalizes within hours of the last dose. IGF-1 drifts back to pre-treatment levels over 2–4 weeks. Cortisol and prolactin elevations, to the extent they were present, normalize quickly. No post-cycle therapy is required — GHRP-6 does not suppress the HPG axis. Weight gained during the on-cycle specifically from ghrelin-driven appetite stimulation may persist or regress depending on whether underlying caloric intake is sustained.

Monitoring & Measurement

Bloodwork & Labs

  • •IGF-1 (serum) — the practical response marker; expect 20–40% rises at typical doses
  • •Fasting glucose and HbA1c
  • •Prolactin and cortisol — GHRP-6 is non-selective, so modest rises are expected; track to distinguish tolerable from problematic
  • •Lipid panel

Functional & Performance Tests

  • •DEXA scan for lean mass
  • •Waist circumference
  • •Daily appetite and hunger rating — GHRP-6's most distinctive effect is strongly orexigenic, and that's the feature that determines whether it suits your goal

When to Test

Baseline, 6 weeks, and 12 weeks.

Interpretation & Notes

GHRP-6's defining characteristic is non-selectivity — unlike ipamorelin, you should expect modest rises in prolactin and cortisol as part of normal pharmacology. A doubling of either warrants dose reduction, or switching to ipamorelin if the goal is GH pulse without adjacent-hormone effects. The appetite-stimulating effect is the practical differentiator: useful if your goal is mass gain during a caloric surplus, actively counterproductive during a cut. Track appetite deliberately — it's the signal that usually determines whether to continue or switch. IGF-1 response is similar in magnitude to other GHRPs (20–40%). Panels via LabCorp, Quest, Marek Health, Ulta Lab Tests.

Common Questions

Why does GHRP-6 increase appetite so much?

GHRP-6 strongly activates the ghrelin receptor, which is the body's primary hunger signaling pathway. This effect is more pronounced with GHRP-6 than with other GHRPs like GHRP-2 or Ipamorelin.

Has GHRP-6 ever been tested in a real clinical trial?

Yes, and the result matters. The Cuban Center for Genetic Engineering and Biotechnology ran COURAGE-2, a Phase III randomized trial of epidermal growth factor plus GHRP-6 in 188 patients with acute ischemic stroke (PMID 42462342). It missed its primary endpoint — in the intention-to-treat analysis there were no differences in modified Rankin Scale, Barthel index or survival. A post-hoc subgroup of 27 patients with severe strokes showed less disability and lower mortality, and the authors argue that subgroup deserves its own trial, but a post-hoc finding in 27 people is a hypothesis, not a result. The trial was also open-label rather than placebo-controlled, serious adverse events were numerically more frequent on treatment (30/95 versus 18/93), and the sponsor's staff occupy the first and senior author positions. Two other things are worth knowing: the dose was 5 mg intravenously twice daily, roughly 50 to 100 times what wellness protocols describe, and this is the only Phase III trial of GHRP-6 in any indication.

Does GHRP-6 actually improve sleep?

Less than its reputation suggests. The one controlled overnight study gave healthy men four 50 mcg intravenous boluses and measured the sleep EEG directly (PMID 7617137). GH rose, as expected, but so did ACTH and cortisol — and on the sleep recording, stage 2 sleep increased while slow-wave sleep did not change. That is a meaningful distinction, because slow-wave sleep is what people usually mean by deep or restorative sleep, and it is what GHRH analogs have been reported to increase. GHRP-6 shifted sleep architecture rather than deepening it, and it did so while raising cortisol overnight, which is not obviously desirable. Subjective reports of better sleep on GHRP-6 are common but have not been matched by objective slow-wave sleep gains.

Why does GHRP-6 need a GHRH analog to work well?

Because it is not a standalone GH switch — it amplifies a signal your hypothalamus has to be sending anyway. When researchers gave healthy men a specific GHRH antagonist before GHRP-6, the GH response collapsed from a maximal increase of 33.8 mcg/l to 6.2 mcg/l (PMID 9543138). In other words, blocking endogenous GHRH removed most of GHRP-6's effect. That is the real pharmacological basis for stacking a GHRP with a GHRH analog like CJC-1295 no-DAC or sermorelin: the two act at different receptors, and the GHRP's own effect depends on the GHRH pathway being active. It also explains why GHRP-6 produces larger pulses when given fasted and at times when endogenous GHRH tone is higher.

How does GHRP-6 compare to other GH secretagogues?

GHRP-6's strong appetite stimulation and cortisol effects set it apart from more selective options like Ipamorelin, which raises GH without the same hunger, cortisol, or prolactin side effects. Most current protocols reach for Ipamorelin or CJC-1295 first, with GHRP-6 reserved for scenarios where appetite stimulation is specifically desired.

Who GHRP-6 Is NOT For

Contraindications
  • •Active or recent-history cancer — GH and IGF-1 elevation may accelerate proliferation of existing malignancies; clinicians universally exclude active cancer from GH-secretagogue protocols. The cachexia-and-appetite use case is the notable exception, where oncology teams may consider ghrelin-receptor agonism with careful weighing of tumor biology, but this falls well outside wellness use.
  • •Pregnancy — no human pregnancy safety data; reproductive-toxicology characterization is absent, and combined GH, cortisol, and appetite effects have not been studied in pregnancy.
  • •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
  • •Diabetes or uncontrolled insulin resistance — GH opposes insulin action, and GHRP-6's cortisol elevation further antagonizes glycemic control. The additional appetite stimulation compounds the metabolic concern in patients for whom caloric intake is already a therapeutic target.
  • •Eating disorders or contexts where appetite stimulation is clinically inappropriate — GHRP-6's acute and pronounced hunger effect is a feature in cachexia and wasting but a meaningful risk in patients with binge-eating disorder, uncontrolled obesity, or other conditions in which driving increased caloric intake is harmful.
  • •Active hypercortisolism, Cushing's disease, or poorly controlled HPA-axis disorders — GHRP-6 stimulates ACTH and cortisol release, and can exacerbate HPA-axis pathology.
  • •Active acromegaly or pituitary adenoma — further stimulation of GH-producing cells is contraindicated.
  • •Pediatric use outside a diagnosed GH deficiency under specialist supervision — development-related signaling effects from unmonitored secretagogue use are a concern.

Drug & Supplement Interactions

Documented clinical drug interactions for GHRP-6 are sparse; the relevant concerns track GHRP-class pharmacology with particular emphasis on the appetite and cortisol effects unique to this compound. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — interact with GH's counter-regulatory effect on glucose and with GHRP-6's added cortisol elevation and appetite stimulation. The combination can substantially destabilize glycemic control, and the appetite-driven behavioral component is not captured by standard drug-interaction frameworks. Patients on weight-management pharmacotherapy, including GLP-1 agonists for obesity, are a particular concern because GHRP-6's hunger effect directly antagonizes the therapeutic goal. Corticosteroids (prednisone, dexamethasone) interact in a dual way: acute glucocorticoid administration can enhance GH response to GHRP-6, while chronic glucocorticoid exposure suppresses spontaneous GH and blunts cumulative IGF-1 gains. Somatostatin analogs (octreotide, lanreotide) directly oppose GH release and will pharmacologically antagonize GHRP-6. Dopamine agonists may be relevant where GHRP-6's prolactin elevation becomes clinically meaningful. Thyroid hormone status matters for GH response. Patients on any regular medication should disclose GHRP-6 use to their prescribing clinician.

Safety Profile

Safety Information

Common Side Effects

Intense hungerWater retentionCortisol elevationTingling

Cautions

  • • Strong appetite stimulation may be problematic
  • • Elevates cortisol more than other GHRPs
  • • Not FDA-approved
  • • Monitor blood sugar levels

What We Don't Know

Long-term metabolic effects of chronic ghrelin receptor activation are not fully understood.

Myths & Misconceptions

Myth

GHRP-6's appetite stimulation is a side effect and not a real use case.

Reality

Appetite stimulation is one of the most pharmacologically distinctive features of GHRP-6 and is exactly what has driven its continued clinical interest in wasting, cachexia, and medication-induced appetite suppression. For those populations it is the feature, not the bug. The feature/side-effect framing depends entirely on the patient and the goal — a body-composition-focused user and a cachectic oncology patient experience the same pharmacology differently.

Myth

GHRP-6 is a weaker version of GHRP-2 or hexarelin — always pick the newer compound.

Reality

GHRP-6 does produce a smaller GH pulse at comparable doses than GHRP-2 or hexarelin, but 'weaker' is not the same as 'worse.' Its particular pharmacology — strong ghrelin-receptor appetite effect, moderate GH-releasing effect, well-characterized safety profile from decades of study — makes it the most appropriate GHRP for some use cases (appetite stimulation) and unnecessary for others (maximal IGF-1 elevation). Evaluating GHRPs on a single 'potency' axis misses the mechanistic differences that should drive compound selection.

Myth

GHRP-6 is FDA-approved because it has been around since the 1980s.

Reality

Duration of research interest is not the same as regulatory approval. GHRP-6 has been studied for more than 40 years without achieving approval in any major market. Its availability in the US has been through compounding-pharmacy and research-chemical channels only, and FDA now lists it in 503B Category 2 (significant safety risks) and 503A Category 3 (nominated without adequate support).

Myth

The appetite stimulation wears off with continued use, so it's not a problem for body-composition users.

Reality

The honest answer is that nobody has measured this properly in humans for GHRP-6. User reports consistently describe the hunger persisting across cycles of weeks to months, particularly with pre-meal dosing, and that is what you would expect from a receptor that does not appear to desensitize much to intermittent stimulation. But there is no placebo-controlled GHRP-6 trial tracking appetite over time — the controlled food-intake data in this peptide family come from GHRP-2 rather than GHRP-6. What animal work does show is that repeated same-day injections blunt the GH response while once-daily dosing over 30 days does not, so tolerance is pathway- and schedule-specific rather than a simple yes or no. Anyone pursuing fat loss should assume the appetite effect persists and plan accordingly, or choose GHRP-2 or ipamorelin instead.

Myth

GHRP-6 is undetectable in drug testing because it is a short peptide and clears quickly.

Reality

LC-MS/MS urinary detection methods for GHRP-6 and its metabolites are well-validated and routinely used in WADA-accredited labs. Short plasma half-life does not equal undetectability — metabolites are excreted in urine and remain measurable for a window after dosing.

Published Research

32 studies

Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor + GHRP-6 in Acute Ischemic Stroke

Hernandez-Bernal et al., J Clin Neurosci 2026 — COURAGE-2, the only Phase III trial of GHRP-6 in any indication, and a NEGATIVE one. 188 patients with acute ischemic stroke were randomized open-label to EGF 75 mcg plus GHRP-6 5 mg IV twice daily for 7 days, or standard care. In the intention-to-treat population no differences were found in modified Rankin Scale, Barthel index or survival, and the authors state the study missed the primary endpoint. A post-hoc subgroup with severe stroke (NIHSS >= 15, n=27) showed lower disability and mortality, which the authors present as hypothesis-generating. Serious adverse events were numerically more frequent on treatment (30/95 vs 18/93, OR 1.92, 95% CI 0.981-3.767), none judged treatment-related. The trial is sponsored by CIGB, whose staff hold the first and senior author positions.

Phase III Clinical TrialPMID: 42462342

EGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences

PreclinicalPMID: 42399524

A discovery-based proteomic approach of epidermal growth factor + GHRP-6 in a model of acute ischemic stroke

PreclinicalPMID: 42258095

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation

PreclinicalPMID: 41901314

Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis

PreclinicalPMID: 41534456

Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.

Zhao et al., J Nanobiotechnology 2025 — a GHRP-6 hydrogel for acute kidney injury, and an example of the formulation work now driving this peptide's preclinical revival. Treatment enhanced tubular epithelial cell survival in the ischemic microenvironment by activating the mTOR-P70 pathway, with spermidine, L-glutamine and acetyl-CoA enriched on metabolomic analysis. Rodent work; no human renal trial.

PreclinicalPMID: 41327290

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.

Berlanga-Acosta et al., Front Pharmacol 2024 — the strongest preclinical cardioprotection signal for GHRP-6. In a doxorubicin cardiotoxicity model, GHRP-6 prevented myocardial fiber loss and ventricular dilation with effective preservation of left ventricular systolic function, upregulating Bcl-2 and preserving mitochondrial integrity. Animal data only; no human cardiac trial of GHRP-6 exists.

PreclinicalPMID: 38873418

Safety and preliminary efficacy of a neuroprotective combined therapy with epidermal growth factor and growth hormone-releasing hexapeptide in acute ischemic stroke (COURAGE-1)

Hernandez-Bernal et al., Front Neurol 2024 — COURAGE-1, the Phase I-II safety study that preceded the Phase III. 36 acute ischemic stroke patients were randomized open-label to EGF 75 mcg with GHRP-6 at 3.5 mg (n=10) or 5 mg (n=10) intravenously twice daily for 7 days, or standard care (n=16), with safety over 6 months as the primary endpoint. It established the 5 mg twice-daily dose carried into COURAGE-2 — roughly 50 to 100 times the microgram-range doses discussed in wellness contexts.

Clinical TrialPMID: 38638315

Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats

PreclinicalPMID: 25194405

Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers

Cabrales et al., Eur J Pharm Sci 2013 — the human pharmacokinetic anchor, in nine healthy men given 100, 200 or 400 mcg/kg as a single IV bolus. Disposition was bi-exponential, with a distribution half-life of 7.6 +/- 1.9 minutes and an elimination half-life of 2.5 +/- 1.1 hours. Note the elimination half-life is hours, not the 15 to 60 minutes often quoted for this peptide.

Phase I Clinical TrialPMID: 23099431

Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment

Clinical TrialPMID: 20602173

Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus

Randomized Controlled TrialPMID: 20189610

Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease

Alaioubi et al., Horm Metab Res 2010 — an honest appraisal of GHRP-6 as a diagnostic alternative to the insulin tolerance test. In 49 patients with suspected HPA dysfunction plus 20 controls, GHRP-6 (1 mcg/kg) activated the axis reliably and without detectable side effects, but at the optimal 299 nmol/l cortisol threshold it reached only 71.0% sensitivity and 77.8% specificity — limited accuracy next to the ITT. Useful context for claims that GHRP-6 is a validated clinical test.

Clinical TrialPMID: 19946832

Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6)

Randomized Controlled TrialPMID: 19453623

Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis

Clinical TrialPMID: 19396632

Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients

Clinical TrialPMID: 18426818

Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH

Randomized Controlled TrialPMID: 17410412

Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH

Clinical TrialPMID: 16832586

Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp

Clinical TrialPMID: 14693411

GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP

Oliveira et al., J Endocrinol Invest 2003 — the clearest demonstration of GHRP-6's off-target HPA activity. In 10 patients with Cushing's disease, a 2 mcg/kg IV bolus raised ACTH from a basal 15.5 +/- 1.7 to a peak 45.1 +/- 9.3 pmol/l and cortisol from 583.0 +/- 90.8 to 1013.4 +/- 194.6 nmol/l, comparable to DDAVP. This is the pharmacology behind the page's cortisol cautions, and the reason GHRP-6 is used as a provocation agent rather than being considered selective.

Randomized Controlled TrialPMID: 12809173

Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism

Animal StudyPMID: 12431802

Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion

Randomized Controlled TrialPMID: 11678828

Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man

Randomized Controlled TrialPMID: 10583306

Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus

Randomized Controlled TrialPMID: 10206449

Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation

Pandya et al., JCEM 1998 — the mechanism keystone, and the reason GHRP-6 is not a standalone GH switch. Using a specific GHRH antagonist in nine healthy men, blocking GHRH almost abolished the GH response to GHRP-6: maximal increase over baseline fell from 33.8 +/- 4.8 to 6.2 +/- 1.8 mcg/l (p<0.0001). GHRP-6 therefore requires endogenous hypothalamic GHRH for a full effect, which is the pharmacological basis for pairing it with a GHRH analog rather than a marketing claim.

Randomized Controlled TrialPMID: 9543138

Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism

Randomized Controlled TrialPMID: 9274702

Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism

Randomized Controlled TrialPMID: 9156038

Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release

Randomized Controlled TrialPMID: 9135702

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.

ReviewPMID: 8887178

Evaluation of pituitary GH reserve with GHRP-6.

ReviewPMID: 8887173

Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood

Micic et al., Clin Endocrinol 1995 — why GHRP-6 behaves differently from GHRH in older adults. Healthy young (22 years) and older (59 years) subjects received GHRH 100 mcg, GHRP-6 90 mcg, or both as IV boluses. GH responses to GHRP-6 alone, and to the combination, did not differ significantly between the age groups, even though the GHRH response declined with age — evidence that the ghrelin-receptor pathway is relatively preserved in ageing.

Randomized Controlled TrialPMID: 7734029

Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man

Frieboes et al., Neuroendocrinology 1995 — the only genuine GHRP-6 sleep and HPA study, and more nuanced than it is usually reported. Four 50 mcg IV boluses overnight in healthy men raised GH (15.4 +/- 9.6 vs 5.5 +/- 4.0 ng/ml after placebo, p<0.02) and also raised ACTH and cortisol. On the sleep EEG, stage 2 sleep increased, but slow-wave sleep did not change — so GHRP-6 alters sleep architecture rather than deepening it, a distinction often lost in secondhand summaries.

Randomized Controlled TrialPMID: 7617137

Quick Facts

Class
Growth Hormone Secretagogue
Tier
C
Evidence
Moderate
Safety
Moderate Data
Updated
Nov 2026
Citations
32PubMed

Also known as

Growth Hormone Releasing Peptide-6

Tags

Growth HormoneAppetiteBody CompositionRecovery

Peptide Families

Growth Hormone Secretagogues

Related Goals

Body Composition

Conditions Discussed

Sarcopenia

Evidence Score

Overall Confidence65%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.